The chemokine receptor type 4 (CXCR4, fusin, CD184), is a G-protein-coupled receptor consisting of a 7-transmembrane region and is the primary receptor for stromal cell-derived factor-1 (SDF-1) also called CXCL12. CXCR4 has become a topic of interest with its involvement in many different cancer types such as breast and lung in particular with implications in ovarian, prostate, colon, ovary and bladder as well. CXCR4 has also been characterized in its involvement as the main receptor supporting viral entry for HIV and evidence also showing that CXCR4 mutations causes WHIM Syndrome, a group of immunodeficiency disease which include warts, Hypogammaglobulinemia, infections and Myelokathexis.
Anti-human CXCR4-SAP eliminates cells expressing human CXCR4 (fusin, CD184).
The following control is recommended for validating the specificity of the beta conjugate: BIgG-SAP mouse (Cat. #IT-74).
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.